Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol

References

• Aebi, H., 1984. Catalase in vitro. Methods in Enzymology, 105, 121–126.
   PubMed Web of Science ®Google Scholar
• Antonarakis, E.S., et al., 2014. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine, 11 (11), 1028–1038.
   Web of Science ®Google Scholar
• Armstrong, A.J., et al., 2019. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. European Urology Oncology, 2 (6), 677–684.
   PubMed Web of Science ®Google Scholar
• Banti, C.N., et al., 2012. Mixed ligand-silver(I) complexes with anti-inflammatory agents which can bind to lipoxygenase and calf-thymus DNA, modulating their function and inducing apoptosis. Metallomics: Integrated Biometal Science, 4 (6), 545–560.,
   PubMed Web of Science ®Google Scholar
• Best, C.J., et al., 2005. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11 (19), 6823–6834.,
   PubMed Web of Science ®Google Scholar
• Boyne, A.F., and Ellman, G.L., 1972. A methodology for analysis of tissue sulfhydryl components. Analytical Biochemistry, 46 (2), 639–653.
   PubMed Web of Science ®Google Scholar
• Buege, J.A., and Aust, S.D., 2008. Microsomal lipid peroxidation. Methods in Enzymology, 52, 302–310.
   Google Scholar
• Gibbons, J.A., et al., 2015. Clinical pharmacokinetic studies of enzalutamide. Clinical Pharmacokinetics, 54 (10), 1043–1055.
   PubMed Web of Science ®Google Scholar
• Gray, P., 1954. The microtomist's formulary and guide. Blakiston, 43 (8), 403–409.
   Google Scholar
• Heinlein, C.A., and Chang, C., 2004. Androgen receptor in prostate cancer. Endocrine Reviews, 25 (2), 276–308.
   PubMed Web of Science ®Google Scholar
• Howe, B., Umrigar, A., and Tsien, F., 1975. Chromosome preparation from cultured cells. Journal of Visualized Experiments, 83, e50203.
   Google Scholar
• Huang, Y., et al., 2018. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncology Letters, 15 (5), 6063–6076.
   PubMed Web of Science ®Google Scholar
• Khan, M.A., Singh, D., and Siddique, H.R., 2019. Animal models in cancer chemoprevention. International Journal of Zoology & Animal Biology, 2369–216X.
   Google Scholar
• Krauwinkel, W., et al., 2017. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects. Journal of Clinical Pharmacy and Therapeutics, 42 (3), 268–275.
   PubMed Web of Science ®Google Scholar
• Marklund, S., and Marklund, G., 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European Journal of Biochemistry, 47 (3), 469–474.
   PubMedGoogle Scholar
• Moreira, R.B., et al., 2017. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget, 8 (48), 84572–84578.
   PubMedGoogle Scholar
• Nigam, N., Prasad, S., and Shukla, Y., 2007. Preventive effects of lupeol on DMBA induced DNA alkylation damage in mouse skin. Food and Chemical Toxicology, 45 (11), 2331–2335.
   PubMed Web of Science ®Google Scholar
• Niknahad, H., et al., 2017. Sulfasalazine induces mitochondrial dysfunction and renal injury. Renal Failure, 39 (1), 745–753.
   PubMed Web of Science ®Google Scholar
• Parveen, S., Tabassum, S., and Arjmand, F., 2016. Human topoisomerase I mediated cytotoxicity profile of l-valine-quercetin diorganotin (IV) antitumor drug entities. Journal of Organometallic Chemistry, 823, 23–33.
   Web of Science ®Google Scholar
• Rotruck, J.T., et al., 1973. Selenium: biochemical role as a component of glutathione peroxidase. Science (New York), 179 (4073), 588–590.
   Google Scholar
• Saltalamacchia, G., et al., 2020. Renal and cardiovascular toxicities by new systemic treatments for prostate cancer. Cancers, 12 (7), 1750.
   PubMed Web of Science ®Google Scholar
• Scher, H.I., et al., 2010. Prostate cancer foundation/department of defense prostate cancer clinical trials consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (London, England), 375 (9724), 1437–1446.
   PubMed Web of Science ®Google Scholar
• Scher, H.I., et al., 2012. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367 (13), 1187–1197.
   PubMed Web of Science ®Google Scholar
• Schmid, W., 1975. The micronucleus test. Mutation Research, 31 (1), 9–15.
   PubMed Web of Science ®Google Scholar
• Sekhar, K.R., et al., 2019. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway. PLoS One, 14 (4), e0214670.
   PubMed Web of Science ®Google Scholar
• Shiota, M., et al., 2017. Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28 (3), 569–575.
   PubMed Web of Science ®Google Scholar
• Shore, N.D., et al., 2019. Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT). Clinical Genitourinary Cancer, 17 (6), 457–463.
   PubMed Web of Science ®Google Scholar
• Siddique, H.R., et al., 2011. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17 (16), 5379–5391.
   PubMed Web of Science ®Google Scholar
• Singh, D., Khan, M.A., and Siddique, H.R., 2019. Apigenin, a plant flavone playing noble roles in cancer prevention via modulation of key cell signaling networks. Recent Patents on Anti-Cancer Drug Discovery, 14 (4), 298–311.
   PubMed Web of Science ®Google Scholar
• Singh, D., Khan, M.A., and Siddique, H.R., 2021. Therapeutic implications of probiotics in microbiota dysbiosis: a special reference to the liver and oral cancers. Life Sciences, 285 (285), 120008.
   PubMed Web of Science ®Google Scholar
• Tan, L.F., et al., 2007. Effects of the ancillary ligands of polypyridyl ruthenium(II) complexes on the DNA-binding and photocleavage behaviors. Polyhedron, 26 (18), 5458–5468.
   Web of Science ®Google Scholar
• Yin, Y., et al., 2017. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Research, 77 (18), 4745–4754.
   PubMed Web of Science ®Google Scholar